Cancer monitor co RealView Medical raises NIS 2m

The company received funding from the Chief Scientist and Trendlines.

The Office of the Chief Scientist, Eli Opper, and Trendlines International Ltd. have jointly invested NIS 2 million in Misgav Venture Accelerator incubator company RealView Medical Ltd. The company is developing an implantable device for long-term monitoring of bladder cancer.

The Misgav incubator is owned by the Trendlines Group.

Muscle invasive transitional cell carcinoma or bladder cancer is characterized by a very high recurrence rate of 70% within the first two years following detection. Early detection increases the chances of preventing a metastastic bladder from penetrating the muscle layer. Patients who have been diagnosed with the cancer are required to undergo an intensive process of uncomfortable and life-threatening monitoring and invasive examinations. The RealView monitoring system offers a simple way of closely yet comfortably monitoring patients.

The CEO of RealView is former Given Imaging VP Haim Akerman.

Published by Globes [online], Israel business news - - on November 18, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018